Article
Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains.
Journal of acquired immune deficiency syndromes (1999) - 1 Jun 2003
Roman François, Gonzalez Dimitri, Lambert Christine, Deroo Sabrina, Fischer Aurélie, Baurith Thérèse, Staub Thérèse, Boulmé Ronan, Arendt Vic, Schneider François, Hemmer Robert, Schmit Jean-Claude
Abstract excerpt
Enfuvirtide (T-20) is the lead compound of the new class of antiretroviral drugs called fusion inhibitors. T-20 resistance-associated mutations located in the heptad repeat 1 (HR-1) domain of gp41 have been described in vitro and in clinical trials. In this study, the authors investigated the pri...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.